Cann started coverage on shares of CRISPR THERAPTC (NASDAQ:CRSP) in a research note issued to investors on Monday morning, The Fly reports. The firm issued a market perform rating on the stock.
CRSP has been the topic of several other reports. Chardan Capital initiated coverage on shares of CRISPR THERAPTC in a report on Monday, March 27th. They issued a buy rating and a $23.50 price target on the stock. SunTrust Banks, Inc. initiated coverage on shares of CRISPR THERAPTC in a report on Thursday, July 13th. They issued a hold rating and a $16.00 price target on the stock. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. CRISPR THERAPTC currently has an average rating of Buy and an average price target of $21.92.
Shares of CRISPR THERAPTC (CRSP) opened at 16.89 on Monday. CRISPR THERAPTC has a 1-year low of $11.63 and a 1-year high of $25.00. The stock has a 50 day moving average of $15.61 and a 200 day moving average of $17.93. The firm’s market cap is $675.55 million.
CRISPR THERAPTC (NASDAQ:CRSP) last released its quarterly earnings results on Thursday, May 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.06. The firm had revenue of $2.70 million during the quarter. Equities research analysts anticipate that CRISPR THERAPTC will post ($2.46) earnings per share for the current fiscal year.
WARNING: This story was originally published by BBNS and is owned by of BBNS. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://baseballnewssource.com/markets/cann-begins-coverage-on-crispr-theraptc-nasdaqcrsp/1235783.html.
In other CRISPR THERAPTC news, Director Kurt Von Emster sold 69,859 shares of CRISPR THERAPTC stock in a transaction on Friday, July 14th. The shares were sold at an average price of $16.84, for a total value of $1,176,425.56. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Samarth Kulkarni sold 11,615 shares of CRISPR THERAPTC stock in a transaction on Tuesday, April 25th. The stock was sold at an average price of $16.78, for a total transaction of $194,899.70. Following the completion of the transaction, the insider now directly owns 137,047 shares in the company, valued at $2,299,648.66. The disclosure for this sale can be found here. Insiders sold 451,845 shares of company stock worth $7,454,471 over the last ninety days. Corporate insiders own 39.98% of the company’s stock.
Several large investors have recently bought and sold shares of CRSP. Credit Suisse AG bought a new stake in CRISPR THERAPTC during the first quarter valued at approximately $1,742,000. Paulson & CO. Inc. bought a new stake in CRISPR THERAPTC during the first quarter valued at approximately $1,099,000. Monashee Investment Management LLC increased its stake in CRISPR THERAPTC by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares during the last quarter. IHT Wealth Management LLC bought a new stake in CRISPR THERAPTC during the first quarter valued at approximately $110,000. Finally, Wellington Management Group LLP increased its stake in CRISPR THERAPTC by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after buying an additional 3,070 shares during the last quarter. Institutional investors and hedge funds own 24.07% of the company’s stock.
About CRISPR THERAPTC
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related companies with our FREE daily email newsletter.